Fractyl Health outlines 2026 De Novo submission plans with pivotal Revita data expected in early Q4

Earnings Call Insights: Fractyl Health (GUTS) Q4 2025

Management View

• CEO Harith Rajagopalan emphasized the company’s conviction in the Revita platform for post-GLP-1 weight maintenance, stating, “Revita is being built for that moment. For those of you who are new to the Fractyl story, Revita is our lead asset…an endoscopic procedure designed to durably maintain weight loss after GLP-1 discontinuation.” He highlighted recent clarity in identifying which patients benefit most from Revita and at what procedural profile, referencing favorable feedback from the FDA on the company’s filing strategy.
• Rajagopalan detailed that analysis of the REMAIN-1 Midpoint Cohort identified a dose response relationship between ablation length and weight maintenance, stating, “We observed a statistically significant…relationship between ablation length and weight maintenance treatment effect at 6 months. Participants who received more than 14 centimeters of ablation regained approximately half the weight of sham.”
• The CEO announced the pivotal REMAIN-1 study has now enrolled over 300 participants, with retention exceeding 95%, and all investigators trained to achieve more than 14 centimeters of ablation.
• Rajagopalan reported favorable early feedback from the FDA on the De Novo classification request, enabling a “more capital efficient, faster and strategically superior path.”
• On commercial infrastructure, he noted, “Revita is the only potential procedural therapy in development for post-GLP-1 weight maintenance, and we believe the commercial infrastructure will be ready to move quickly upon clearance.”
• CFO Lara Weber stated, “Research and development expenses were $16.5 million for the quarter ended December 31, 2025, compared to $20.3 million for the same period in 2024.” She also noted, “We reported a net loss of $43.7 million for Q4 2025 compared to $25 million in Q4 2024. However, the $20.2 million of the increase was a noncash accounting change in the fair value of our warrant liabilities, which does not reflect a change in our underlying operating performance.”
• Weber added that the company ended the year with approximately $81.5 million in cash and cash equivalents and expects this, plus subsequent warrant proceeds, to fund operations into early 2027.
• Rajagopalan clarified, “We have closed our ATM facility, and we do not have plans to raise capital before we have pivotal data in hand. Our runway extends into early 2027.”

Outlook

• Management expects to deliver top line 6-month primary endpoint data from the REMAIN-1 pivotal study in early Q4 2026 and anticipates De Novo submission in late Q4 2026. The pivotal study is powered at over 90% to achieve success across both co-primary endpoints: percent body weight regain at 6 months and proportion of patients maintaining at least 5% total body weight loss at 1 year.
• CEO Rajagopalan stated, “We remain on track to deliver top line 6-month primary endpoint data in early Q4 2026. With this positive feedback now in hand, ahead of schedule, we are on track for De Novo submission in late Q4 2026 with 6-month pivotal data in hand.”

Financial Results

• Weber reported that adjusted EBITDA was negative $21.2 million for Q4 2025 compared to negative $22.1 million for Q4 2024, reflecting a decrease in operating expenses.
• The company’s cash position was $81.5 million at year end, with an additional $4.1 million from warrant exercises in January 2026.
• Operating expenses for the quarter were $1.9 million lower than the same period in 2024, driven by strategic reprioritization and reduced costs from pausing the REVITALIZE-1 study.

Q&A

• Angela Qian, Canaccord Genuity: Asked about ablation length standardization and future physician training. Rajagopalan explained, “What is clear is that the ablation length for weight effects is greater than or equal to 16 centimeters. That will be our operating standard going forward.”
• Michael DiFiore, Evercore ISI: Inquired about the De Novo pathway and efficacy vs. safety. Rajagopalan responded, “The De Novo pathway determination versus, say, a PMA determination is principally a safety consideration…The efficacy threshold for a De Novo is reasonable assurance of safety and effectiveness.”
• Chi Meng Fong, BofA Securities: Sought color on post-hoc analysis and pivotal cohort confidence. Rajagopalan confirmed, “Mean and median ablation length are greater than 16 centimeters and the average ablation length is longer than it was in the Midpoint Cohort. All of this translates to a high degree of conviction in the pivotal study.”
• Michael Ulz, Morgan Stanley: Asked about physician training duration. Rajagopalan stated, “It takes less than 3 to 4 cases to train a physician to perform ablations.”
• Jeffrey Cohen, Ladenburg Thalmann: Asked about future CPT code timing and payer discussions. Rajagopalan said, “We’re anticipating filing for the Category III CPT code in June of this year…should go into effect in the summer of ’27, July 1. And we are also intending to file for a transitional pass-through payment through CMS immediately upon FDA authorization.”
• Joseph Pantginis, H.C. Wainwright: Inquired about regulatory submission steps. Rajagopalan outlined, “There are 3 main packages to the regulatory submission. There is a design history file…a manufacturing file…and then there will be clinical data.”

Sentiment Analysis

• Analysts pressed for clarity on standardization, regulatory pathways, and commercialization, reflecting a slightly positive but cautious tone as they sought details on pivotal data, real-world feasibility, and reimbursement.
• Management’s tone was confident and precise during prepared remarks and Q&A, frequently referencing operational achievements, upcoming catalysts, and regulatory progress. Statements such as “We are confident that each of those independently and collectively will drive larger and compounding treatment effects” and “Our runway extends into early 2027” signaled assurance in the company’s positioning.
• Compared to the previous quarter, management maintained a confident tone but provided more specificity regarding operational metrics, regulatory timelines, and capital strategy. Analysts continued to probe for granular details but showed increased focus on execution and pivotal trial outcomes.

Quarter-over-Quarter Comparison

• The current quarter featured expanded emphasis on dose-response findings, ablation length standardization, and pivotal study powering, as well as more explicit guidance on regulatory and reimbursement milestones. In contrast, the prior quarter focused broadly on clinical momentum, randomization progress, and durability data from real-world registries.
• Guidance language shifted from general confidence in trial progress to explicit timelines for pivotal data release and De Novo submission.
• Analysts’ questions evolved from durability and manufacturing readiness to detailed operational metrics, regulatory processes, and commercialization pathways.
• Management’s confidence remained high, with additional clarity on financial runway and no planned capital raises before pivotal data.

Risks and Concerns

• Management identified the need to standardize ablation length as a key procedural driver for Revita’s efficacy and has incorporated this into secondary endpoints and training for the pivotal study.
• Regulatory risk was addressed with early FDA feedback on De Novo classification and preparation for a comprehensive submission package.
• Analysts probed for risks related to real-world standardization, training scalability, and payer adoption, all of which management addressed with data on operator performance and planned reimbursement strategies.

Final Takeaway

Fractyl Health’s management underscored a catalyst-rich year ahead, marked by planned pivotal data readout in early Q4 2026 and a targeted De Novo submission in late Q4 2026, with no planned capital raises until then. The company’s clarity on Revita’s dose-response relationship, operational progress in pivotal enrollment and physician training, as well as early regulatory and reimbursement groundwork, position Fractyl to deliver what it describes as the first procedural therapy for weight maintenance post-GLP-1 discontinuation, supported by a strong cash runway into early 2027.

Read the full Earnings Call Transcript